palmoplantar psoriasis. Other psoriasis
Conditions
Interventions
The present study is a clinical trial conducted on 16 patients with predominantly palmoplantar psoriasis (with or without biopsy) who are referred to Razi Hospital, meet the inclusion criteria, and co
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients aged 18 to 70 years with predominantly palmoplantar psoriasis who have provided informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: Patients who have received other systemic medications for palmoplantar psoriasis in the past month Pregnant and breastfeeding women Patients with a history of cardiac, renal, hepatic, or hematologic diseases, history of thrombosis, lymphoma, and other malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion extent is assessed on a 0 to 6 grading scale. Timepoint: Intervals of 0, 4, 8, and 12 weeks. Method of measurement: The extent of lesions is evaluated using a standardized 0 to 6 scoring system based on body surface area (BSA) involvement, where:0 = no lesions? 1 = <10% BSA? 2 = 10-29% BSA? 3 = 30-49% BSA? 4 = 50-69% BSA? 5 = 70-89% BSA? 6 = 90-100% BSA.;Erythema of lesions is assessed on a 0 to 4 grading scale. Timepoint: Intervals of 0, 4, 8, and 12 weeks. Method of measurement: Lesion erythema is clinically evaluated using a standardized 0 to 4 scoring system, where:0 = no erythema? 1 = slight erythema? 2 = moderate erythema? 3 = marked erythema? 4 = severe erythema.;Scaling of lesions is assessed on a 0 to 4 grading scale. Timepoint: Intervals of 0, 4, 8, and 12 weeks. Method of measurement: Lesion scaling is clinically evaluated using a standardized 0 to 4 scoring system, where:0 = no scaling ? 1 = slight scaling ? 2 = moderate scaling ? 3 = marked scaling ? 4 = severe scaling.;Lesion induration is assessed on a scale from 0 to 4. Timepoint: Intervals of 0, 4, 8, and 12 weeks. Method of measurement: Lesion induration is clinically evaluated using a standardized 0 to 4 scoring system, where:0 = no induration ? 1 = slight induration ? 2 = moderate induration ? 3 = marked induration ? 4 = severe induration.;The patient’s quality of life is assessed on a scale from 0 to 30. Timepoint: Intervals of 0, 4, 8, and 12 weeks. Method of measurement: Evaluation based on completion of the Dermatology Life Quality Index (DLQI) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRaziyeh Vahedi
Tehran University of Medical Sciences
Outcome results
None listed